Abstract

The low membrane permeability of lipophilic drugs was resolved using liposomes as a solubilizing agent and the precise size control of them is a significant parameter in drug carrier technology. Here, we have established a microfluidic octanol-assisted liposome assembly method to produce a surfactant-assisted liposome which has merged by the cytoskeleton drug (Taxotere) encapsulation in a single process step, then a complete microfluidic cellular analysis was performed in trapping cell device with an optofluidic assay for quantifying drug permeability. The optimization of process variables resulted in the formation of liposomes with particle size 6.75 ± 0.5 µm and monodispersity 6.2%, representing encapsulation efficiency and loading capacity of 65.49 ± 3.08% and 10.16 ± 0.32%, respectively. Qualitative and quantitative studies of cellular uptake in MCF-7 cell line that was cultured in the cell trapping chip indicated a significant increase in cellular uptake of carboxyfluorescein-loaded liposomes, suggesting endocytic mechanisms. The drug-loaded liposomes with an IC₅₀ value of 0.55 ± 0.04 μg mL⁻¹ have shown a higher level of cellular inhibition and apoptosis in cells than free Taxotere (2.48 ± 0.01). Furthermore, real-time analysis of the dynamic labeling assay for live/dead cells was investigated. Our data revealed that lab-on-a-chip platforms for the time-lapse fluorescence imaging were applied for drug screening routines.

Graphic abstract

Cytoskeleton drugs encapsulated in liposome using microfluidic approaches and investigation of programmed cell death assay.

中文翻译：

---

使用微流控平台研究封装的骨架药物脂质体对程序性细胞死亡的影响

摘要

使用脂质体作为增溶剂解决了亲脂性药物的低膜通透性，对它们的精确尺寸控制是药物载体技术中的重要参数。在这里，我们建立了一种微流体辛醇辅助脂质体的组装方法，以生产一种表面活性剂辅助脂质体，该脂质体通过细胞骨架药物（Taxotere）的包封在单个过程步骤中融合，然后在捕获细胞装置中进行了完整的微流体细胞分析。用于量化药物渗透性的光流分析。工艺变量的优化导致形成的脂质体的粒径为6.75±0.5 µm，单分散性为6.2％，分别代表了封装效率和载量为65.49±3.08％和10.16±0.32％。在细胞捕获芯片中培养的MCF-7细胞系中细胞摄取的定性和定量研究表明，羧基荧光素负载的脂质体的细胞摄取显着增加，表明胞吞机制。具有IC的载药脂质体₅₀的0.55±0.04μgmL ^-1值显示细胞中的细胞抑制和凋亡水平高于游离的Taxotere（2.48±0.01）。此外，研究了活/死细胞动态标记测定的实时分析。我们的数据显示，用于延时荧光成像的芯片实验室平台已应用于药物筛选程序。

图形摘要

使用微流体方法封装在脂质体中的细胞骨架药物和程序性细胞死亡测定法的研究。